Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 5/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20420476 | 0.87 | LMNA (0.51) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL22015537 | 0.80 | CASP2 (0.50) | CNR1HPGDFAAHCASP2DNM1 | |
| SCHEMBL17229451 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL20022932 | 0.77 | LMNA (0.44) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL17070318 | 0.75 | ALDH1A1 (0.35) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL17070320 | 0.75 | LPAR1 (0.37) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL19262105 | 0.75 | NOD1 (0.49) | — | |
| SCHEMBL21478093 | 0.73 | ALDH1A1 (0.43) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL24709146 | 0.71 | LMNA (0.53) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL25853656 | 0.71 | MEN1 (0.54) | ALDH1A1LMNAPKMCNR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822313-B2 | Selective sulfonation of benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200157056-A1 | SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822313-B2 | Selective sulfonation of benzodiazepine derivatives | GABRA2, GABRA4, GABRA1 | ALDH1A1 1518/4885LMNA 2822/4885PKM 3254/4885 |
| US-20200157056-A1 | SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES | GABRA2, GABRA4, GABRA1 | ALDH1A1 1518/4885LMNA 2822/4885PKM 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.